CN111423514A - 一种氟代tf-muc1糖肽缀合物及其制备方法和应用 - Google Patents
一种氟代tf-muc1糖肽缀合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111423514A CN111423514A CN202010118019.1A CN202010118019A CN111423514A CN 111423514 A CN111423514 A CN 111423514A CN 202010118019 A CN202010118019 A CN 202010118019A CN 111423514 A CN111423514 A CN 111423514A
- Authority
- CN
- China
- Prior art keywords
- glycopeptide
- muc1
- integers
- formula
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000002068 Glycopeptides Human genes 0.000 title claims abstract description 96
- 108010015899 Glycopeptides Proteins 0.000 title claims abstract description 96
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title claims abstract description 88
- 125000001153 fluoro group Chemical group F* 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 14
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 12
- 108010081954 galacto-N-biose Proteins 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 7
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 4
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 229940118376 tetanus toxin Drugs 0.000 claims description 4
- 108060003552 hemocyanin Proteins 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 abstract description 17
- 239000000427 antigen Substances 0.000 abstract description 17
- 102000036639 antigens Human genes 0.000 abstract description 17
- 108091007433 antigens Proteins 0.000 abstract description 17
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract description 14
- 230000005847 immunogenicity Effects 0.000 abstract description 8
- 238000011068 loading method Methods 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000011347 resin Substances 0.000 description 38
- 229920005989 resin Polymers 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000010532 solid phase synthesis reaction Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- -1 glycopeptide compound Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010008707 Mucin-1 Proteins 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- DFSFLZCLKYZYRD-UHFFFAOYSA-N 3,4-diethoxycyclobut-3-ene-1,2-dione Chemical compound CCOC1=C(OCC)C(=O)C1=O DFSFLZCLKYZYRD-UHFFFAOYSA-N 0.000 description 1
- CHIDDYZONKDHLG-UHFFFAOYSA-N 3-[2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCCOCCC(=O)O)C3=CC=CC=C3C2=C1 CHIDDYZONKDHLG-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical class [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000386 donor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000937 glycosyl acceptor Substances 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940060155 neuac Drugs 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域
本发明属于肿瘤疫苗研制技术领域,尤其是一种氟代TF-MUC1糖肽缀合物及其制备方法和应用。
背景技术
TF抗原是Core 2O-聚糖的前体,由未唾液酸化的Core 1结构(Galβ1-3GalNAcαSer/Thr) 组成,最初是由Thomsen和Friedenreich在红细胞中决定血型的糖蛋白上发现的。它在正常细胞上会被进一步糖基化或被唾液酸修饰所掩蔽。然而,TF抗原暴露于很多癌症细胞表面,包括乳腺癌、肺癌、膀胱癌、前列腺癌和胰腺癌等。所以,TF抗原的表达已经作为检测肿瘤的工具并且作为愈后的标准,其分布密度可以用来预测癌症的组织病理学分级、癌细胞的侵袭潜力,以及乳腺、膀胱和前列腺肿瘤早期复发的可能性。Georg Springer是乳腺癌中TF抗原研究的先驱,他首先表明所有乳腺癌都表达TF抗原,而且来使用单克隆抗体研究证明TF 抗原在正常上皮或乳腺细胞中仅低水平表达。
黏蛋白1(MUC1)是一种I型跨膜糖蛋白,由两个亚基组成,高度糖基化的细胞外N端结构域(MUC1-N),从细胞中突出表面可达200~500nm,由20个氨基酸残基串联重复序列(HGVTSAPDTRPAPGSTAPPA)组成,重复数目从20到120个不等,同时序列中的有五个潜在的翻译后O-糖基化位点,位于其中的丝氨酸(Ser)和苏氨酸(Thr)残基上。MUC1属于肿瘤相关抗原高表达的范畴,在许多癌症的肿瘤细胞中都存在MUC-1高表达和异常糖基化。研究表明在近86%的腺癌中都有异常MUC-1的高表达。肿瘤细胞表面的糖基化模式发生了改变,通常被肿瘤相关糖抗原(TACA)覆盖。借此,MUC1通过TACA与凝集素相互作用而发挥的致癌功能。这些相互作用往往导致前肿瘤微环境的产生,有利于肿瘤的进展、转移和肿瘤的逃避。同时,由于肿瘤细胞表面MUC1的糖基侧链变短,新的肽段表位出现,有过量的Tn(GalNAcα-O-Ser/Thr)、TF(Galβ1-3GalNAcα-O-Ser/Thr)、sTn NeuAcα2-6-GalNAcα-O-Ser/Thr等抗原的表达,具有高免疫原性,因此MUC1成为一种非常有潜力的治疗性肿瘤疫苗的靶标。
长期以来一直流行使用蛋白质缀合物制备候选疫苗。不同的蛋白质载体如BSA(牛血清白蛋白)、KLH(匙孔血蓝蛋白)、TTox(破伤风类毒素)等已经被用来与MUC1糖肽缀合以产生免疫应答,因为这些蛋白质载体含有许多表位抗原,具有高度免疫原性。
除了将MUC1糖肽与载体蛋白偶联外,还可以通过对肿瘤相关糖抗原(TACAs)衍生或修饰来进一步增强MUC1糖肽疫苗的免疫原性。由于MUC1糖肽属于内源性结构,是T细胞非依赖性的自身抗原,因此易被免疫系统所耐受,所以为了提高这些内源性结构的免疫原性,可以使用氟原子替代糖分子中的羟基,以期利用电子等排性,增强糖抗原的代谢稳定性和生物利用度,从而进一步提高MUC1糖肽抗原的免疫原性。
通过检索,尚未发现与本发明专利申请相关的专利公开文献。
发明内容
本发明目的在于克服现有技术中的不足之处,提供一种氟代TF-MUC1糖肽缀合物及其制备方法和应用,该氟代TF-MUC1糖肽缀合物能够激发高滴度的IgG抗体水平,因此能够应用在疫苗方面中。
本发明解决其技术问题所采用的技术方案是:
一种氟代TF-MUC1糖肽缀合物,所述糖肽缀合物的结构通式如下:
其中,糖肽是如下通式(I)中的任一糖肽:
式(Ⅰ)和式(Ⅱ)中:
m是0到30中的任意一个整数;
R=GalNAcα,GalNAcβ,GlcNAcα,GlcNAcβ,Galβ1-3GalNAcα,Galβ1-3GalNAcβ或上述糖基的氟代衍生物;
连接体是糖肽与载体蛋白直接或间接连接后得到的结构部分;
n是载体蛋白连接的寡糖的数量,n是0到30中的任意一个整数;
载体蛋白选自:牛血清白蛋白、人血清白蛋白、血蓝蛋白、破伤风毒素、白喉毒素或白喉毒素无毒突变体。
而且,所述糖肽缀合物的结构通式为如下之一:
式中,j1是0到10中的任意一个整数,j2是0到10中的任意一个整数,j3是0到10中的任意一个整数,n是0到30中的任意一个整数。
而且,所述糖肽缀合物的结构通式如下:
式中,j1是0到10中的任意一个整数,n是0到30中的任意一个整数。
而且,所述糖肽缀合物的结构通式如下:
式中,j1是0到10中的任意一个整数,n是0到30中的任意一个整数。
而且,所述糖肽缀合物的结构通式如下:
式中,j3是0到10中的任意一个整数,n是0到30中的任意一个整数。
而且,所述糖肽缀合物的结构通式如下:
式中,j3是0到10中的任意一个整数,n是0到30中的任意一个整数。
一种如上所述的氟代TF-MUC1糖肽缀合物的制备方法,包括如下技术路线:
如上所述的氟代TF-MUC1糖肽缀合物在制备疫苗方面中的应用。
而且,所述疫苗为肿瘤疫苗。
本发明取得的优点和积极效果为:
1、本发明氟代TF-MUC1糖肽缀合物中,糖肽的化学结构是明确且单一的,可以通过化学方法大量合成。
2、本发明选择的连接体容易被活化,可高效地实现与载体蛋白的偶联,提高载体蛋白的载糖肽量。
3、本发明氟原子的引入可以增强糖抗原中糖苷键的稳定性,从而提高糖肽抗原的代谢稳定性、脂溶性和生物利用度,解决了天然肿瘤相关MUC1糖肽免疫原性差和不稳定的问题。
4、酶联免疫吸附测定显示,氟代MUC1糖肽抗原免疫后的血清中的抗体能够识别天然 MUC1,实现交叉识别。
5、动物实验表明,该氟代TF-MUC1糖肽缀合物能够激活有效的T细胞反应,产生高滴度的IgG抗体水平。
6、本发明肿瘤疫苗作为治疗性疫苗应用,能够降低治疗过程中肿瘤化学药物的用量和减少抗癌药的副作用,提高癌症患者的生存率。
附图说明
图1为本发明中化合物7的1HNMR谱图;
图2为本发明中化合物10的MALDI-TOF图;
图3为本发明中化合物10的分析HPLC图;
图4为本发明中氟代TF-MUC1糖肽缀合物的MALDI-TOF图;
图5为本发明中氟代TF-MUC1糖肽缀合物的特异性三免抗体滴度图。
具体实施方式
下面详细叙述本发明的实施例,需要说明的是,本实施例是叙述性的,不是限定性的,不能以此限定本发明的保护范围。
本发明中所使用的原料,如无特殊说明,均为常规的市售产品;本发明中所使用的方法,如无特殊说明,均为本领域的常规方法。
一种氟代TF-MUC1糖肽缀合物,所述糖肽缀合物的结构通式如下:
其中,糖肽是如下通式(I)中的任一糖肽:
式(Ⅰ)和式(Ⅱ)中:
m是0到30中的任意一个整数;
R=GalNAcα,GalNAcβ,GlcNAcα,GlcNAcβ,Galβ1-3GalNAcα,Galβ1-3GalNAcβ或上述糖基的氟代衍生物;
连接体是糖肽与载体蛋白直接或间接连接后得到的结构部分;
n是载体蛋白连接的寡糖的数量,n是0到30中的任意一个整数;
载体蛋白选自:牛血清白蛋白(BSA)、人血清白蛋白(HSA)、血蓝蛋白(KLH)、破伤风毒素(TT)、白喉毒素(DT)或白喉毒素无毒突变体(CRM197)。
较优地,所述糖肽缀合物的结构通式为如下之一:
式中,j1是0到10中的任意一个整数,j2是0到10中的任意一个整数,j3是0到10中的任意一个整数,n是0到30中的任意一个整数。
较优地,所述糖肽缀合物的结构通式如下:
式中,j1是0到10中的任意一个整数,n是0到30中的任意一个整数。
较优地,所述糖肽缀合物的结构通式如下:
式中,j1是0到10中的任意一个整数,n是0到30中的任意一个整数。
较优地,所述糖肽缀合物的结构通式如下:
式中,j3是0到10中的任意一个整数,n是0到30中的任意一个整数。
较优地,所述糖肽缀合物的结构通式如下:
式中,j3是0到10中的任意一个整数,n是0到30中的任意一个整数。
一种如上所述的氟代TF-MUC1糖肽缀合物的制备方法,包括如下技术路线:
氟代TF-MUC1糖肽片段是通过Fmoc保护的多肽固相合成方法实现,即通过活化树脂、加载氨基酸,脱除Fmoc保护基,根据需要重复第二和第三步骤多次,最后加载Linker部分,脱除Fmoc保护基,裂解,最终得到含保护基的糖肽,之后用水合肼脱除保护基,然后使用活泼酯活化糖肽,最后,将活化的糖肽与蛋白偶联制备出氟代TF-MUC1糖肽缀合物。
上述制备方法,只表示制备本发明的式(II)化合物的方法之一例子。本发明化合物的制备方法并不仅限于这些方法,在本说明书的实施例中,由于更具体地说明了本发明化合物的制备方法,所以,本领域的人员,根据上述说明和具体实施例的说明,根据需要,对此加以适当的修改,就能制造出氟代TF-MUC1糖肽缀合物。
具体地,本发明氟代TF-MUC1糖肽缀合物通用的一种合成方法,步骤如下:
(1)糖抗原的合成反应
取糖基供体(2.0个当量),糖氨基酸受体溶于无水二氯甲烷,室温搅拌30min后将体系置于-20℃低温反应浴中,向其中滴加三氟甲磺酸三甲基硅酯(0.4个当量),反应1h。经TLC检测显示反应完成,滴加三乙胺猝灭。经过滤,减压浓缩,硅胶柱层析分离纯化,得到中间体1(所用的洗脱液为石油醚(PE)/乙酸乙酯(EA))。后续是对中间体1进行保护基转换操作,即将中间体1溶解于80%冰醋酸水溶液中,90℃反应4h,脱除苄叉保护基,随后在四氢呋喃/醋酐/冰醋酸(3:2:1,v/v/v)的混合溶液中,加入锌粉(15.0个当量)和饱和硫酸铜溶液,将叠氮基还原为氮乙酰基,之后,在吡啶/醋酐(50.0个当量)条件下将裸露的羟基进行乙酰化保护,最后以甲醇为溶剂,加入10%钯碳,通入氢气,常温反应1h,TLC监测反应完成后,过滤,减压浓缩,硅胶柱层析得到目标产物(所用的洗脱液为石油醚(PE) /乙酸乙酯(EA))。
(2)固相合成反应
首先,活化树脂阶段,取2-chlorotrityl chloride树脂(1.0个当量)于固相合成管中,室温真空干燥过夜,加入无水DCM,28℃,240r/min振摇30min,抽干;第二步,加载首个氨基酸,称取Fmoc保护的目标氨基酸(2.0个当量),溶解于DCM中,超声溶解后加入固相合成管中,然后加入N,N-二异丙基乙胺(9.0个当量)。将固相合成管置于摇床(28℃, 240r/min)振摇3h,加入甲醇,继续振摇30min,过滤,用DMF/MeOH/DCM交替清洗树脂,最后将抽干,真空干燥;第三步,脱除Fmoc:向树脂中加入30%的吗啉(200.0个当量),振摇30min后,抽干,重复该操作一次,然后取少量树脂于试管中,滴加茚三酮/苯酚显色剂,将试管置于120℃油浴中,5min后观察树脂颜色变化,若树脂全部变蓝色则表示反应完全。反应完成后用DMF/异丙醇/DMF依次清洗树脂,抽干;第四步,加载第二个氨基酸,称取 Fmoc保护的目标氨基酸(3.0个当量)、HBTU(3.0个当量)和HOBt(3.0个当量),溶解于DMF中,后续操作同上述第二步和第三步;第五步,加载第三个糖氨基酸,称取步骤(1) 中制备的糖抗原(1.5个当量)、HATU(2.0个当量)和HOAt(2.0个当量),溶解于NMP 中,加入N-甲基吗啉(4.0个当量),后续操作同上述第二步和第三步;第六步,加载第四个和第五个氨基酸条件同第四步;第七步,加载Linker部分:加入Fmoc保护的Linker、HATU (3.0个当量)和HOAt(3.0个当量),溶解于N-甲基吡咯烷酮中,加入N-甲基吗啉(6.0 个当量),后续操作同上述第二步和第三步;最后一步,裂解反应:配制裂解液 (TFA:TIS:H2O=15:0.9:0.9),加入树脂中,振摇(34℃,240r/min)2h后,过滤,冷却,重结晶得到糖肽化合物。
(3)糖肽缀合物的制备
糖肽脱保护:取上述(2)中制备的糖肽化合物于小烧瓶中,加入一定体积的水合肼,室温条件下搅拌3h,反应完成后旋蒸浓缩,C18反相半制备柱纯化,得到脱保护的糖肽化合物。
活化糖肽:将脱保护的糖肽溶解于乙醇(EtOH)和水(H2O)的混合液中(EtOH:H2O=1:1),加入活泼酯(6.0个当量),滴加饱和碳酸钠溶液调节反应液pH至8.0,室温反应3h。之后,浓缩,用C18反相半制备柱纯化,冻干,得到活化的糖肽。
糖肽蛋白缀合物的合成:按照48:1的摩尔比取活化的糖肽和蛋白(糖肽:蛋白=48:1) 溶于缓冲溶液(0.07M Na2B4O7/0.035M NaHCO3,pH9.0)中,将混合液置于摇床上室温缓慢振摇2d。之后,经超滤,冻干,得到糖肽蛋白缀合物。
更具体地,相关制备及检测如下:
一、N-芴甲氧羰基-O-(2,3,4-三-O-乙酰基-6-脱氧-6F-β-D-吡喃半乳糖基-(1→3)-2-乙酰氨基-2-脱氧-4,6-二-O-乙酰-α-D-吡喃半乳糖基)-L-苏氨酸7的合成
首先,在50mL支口烧瓶中加入分子筛,600℃下烘烤20min,待其冷却至室温后,称取氟代半乳糖糖基供体1(410mg,905.55μmol),糖基受体2(320mg,452.78μmol) 加入到烧瓶中,加入10mL无水二氯甲烷,常温条件下搅拌30min后将体系置于-20℃中,向其中滴加三氟甲磺酸三甲基硅酯(TMSOTf,35μL,181.11μmol),-20℃反应1h。TLC (PE:EA=2:1,Rf=0.3)监测至反应结束后,滴加三乙胺猝灭促进剂,直至体系pH呈中性。利用带有硅藻土的砂板漏斗抽滤除去分子筛,旋蒸除去无水二氯甲烷,采用硅胶柱分离纯化,得到化合物3(340mg,341.02μmol,75%)。然后,将化合物3溶解于80%冰醋酸水溶液中,90℃油浴中反应脱除苄叉保护基,得到化合物4。随后在四氢呋喃/醋酐/冰醋酸(3:2:1, v/v/v)的混合溶液中,用锌粉将叠氮基还原为氮乙酰基,并在吡啶/醋酐条件下将裸露的羟基进行乙酰化保护,得到化合物6。最后以甲醇为溶剂,在10%钯碳及氢气流中进行氢解反应,脱除苏氨酸上的苄基。通过五步,以31%的总产率得到化合物7(如图1所示,126mg,137.12 μmol)。1H NMR(400MHz,MeOD)δ7.81(d,J=7.4Hz,2H),7.63(dd,J=38.6,6.1Hz,2H), 7.43-7.28(m,4H),5.46-5.32(m,2H),5.00(d,J=6.2Hz,2H),4.67(d,J=6.8Hz,1H),4.52(m, 4H),4.41-4.30(m,2H),4.23(m,3H),4.13(dd,J=11.4,4.5Hz,1H),4.07-3.87(m,3H),2.11(d,J =9.2Hz,6H),2.02(d,J=10.0Hz,6H),1.97(s,3H),1.93(s,3H),1.22(d,J=6.3Hz,3H).13C NMR(101MHz,MeOD)δ171.82,170.93,170.64,170.10,169.74,143.85,141.31,127.48,126.84,124.69,119.65,101.00,99.51,81.49,76.01,73.28,71.35,71.12,70.74,69.79,68.73,67.46,67.12, 66.22,62.78,58.46,21.88,19.58-18.96,17.78.19F NMR(376MHz,CDCl3)δ-232.54(s).
二、氟代TF-MUC1糖肽8的固相合成
氟代TF-MUC1糖肽片段是通过Fmoc保护的多肽固相合成方法实现的。具体合成步骤如下:
(1)活化树脂:首先取2-chlorotrityl chloride resin(0.34mmol/g,100mg)于50mL固相合成管中,室温真空干燥过夜,然后向固相合成管中加入2mL无水DCM并将其置于摇床 (28℃,240r/min)振摇30min,最后将液体抽滤干净。
(2)加载首个氨基酸Fmoc-Pro-OH:称取Fmoc-Pro-OH(35.4mg,0.11mmol)于2mL 无水DCM中,超声溶解后加入盛有活化树脂的固相合成管中,然后再向其中慢慢加入N,N- 二异丙基乙胺(DIEA,52μL)。将固相合成管置于摇床(28℃,240r/min)振摇3h后,向反应混合液中加入甲醇(15μL),继续振摇30min后,滤除反应液,依次用2mL DMF/MeOH/DCM交替清洗树脂,每次5min。最后将树脂抽干并真空干燥过夜。
(3)脱除Fmoc:向树脂中加入2mL 30%的吗啉,摇床振摇30min后抽干反应液,然后将该操作重复一次,反应结束后,取少量树脂于小试管中,滴加茚三酮/苯酚显色剂,将小试管置于120℃油浴中,5min后观察树脂颜色变化,若树脂全部变蓝则表示反应完全。反应完成后用DMF/异丙醇/DMF依次清洗树脂,清洗完后将树脂抽干。
(4)加载第二个氨基酸Fmoc-Arg(Pbf)-OH:称取Fmoc-Arg(Pbf)-OH(68.1mg,0.11mmol)、HBTU(39.8mg,0.11mmol)、HOBt(14.2mg,0.11mmol)于2mLDMF中,超声溶解后加入盛有树脂的固相合成管中,然后再向其中慢慢加入N,N-二异丙基乙胺(DIEA, 35μL)。将固相合成管置于摇床(28℃,240r/min)振摇3h。反应结束后,取少量树脂于小试管中,通过上述显色反应观察树脂显色后若全部为白色则表示反应完全。反应完成后用 DMF/异丙醇/DMF依次清洗树脂,清洗完后将树脂抽干。脱除Fmoc操作同(3)。
(5)加载第三个氨基酸:称取先前合成的氟代TF抗原(47mg,0.05mmol)、HATU(30mg,0.08mmol)、HOAt(9.3mg,0.068mmol)于2mLNMP中,超声溶解后加入盛有树脂的固相合成管中,然后再向其中慢慢加入N-甲基吗啉(NMM,15μL)。将固相合成管置于摇床(28℃,240r/min)振摇18h。反应结束后,取少量树脂于小试管中,通过上述显色反应观察树脂显色后若全部为白色则表示反应完全。反应完成后用DMF/异丙醇/DMF依次清洗树脂,清洗完后将树脂抽干。脱除Fmoc操作同(3)。
(6)加载第四个氨基酸Fmoc-Asp(OtBu)-OH:称取Fmoc-Asp(OtBu)-OH(43.2mg,0.11 mmol)、HBTU(39.8mg,0.11mmol)、HOBt(14.2mg,0.11mmol)于2mLDMF中,其余操作同(4)。脱除Fmoc操作同(3)。
(7)加载第五个氨基酸Fmoc-Pro-OH:称取Fmoc-Pro-OH(35.4mg,,0.11mmol)、HBTU(39.8mg,,0.11mmol)、HOBt(14.2mg,,0.11mmol)于2mLDMF中,其余操作同(4)。脱除Fmoc操作同(3)。
(8)加载Linker:取Fmoc-NH-PEG3-CH2CH2COOH(45.2mg,0.102mmol)、HATU(38.8mg,0.102mmol)、HOAt(13.9mg,0.102mmol)于2mLNMP中,超声溶解后加入盛有树脂的固相合成管中,然后再向其中慢慢加入N-甲基吗啉(23μL,0.2umol)。将固相合成管置于摇床(28℃,240r/min)振摇3h。反应结束后,取少量树脂于小试管中,通过上述显色反应观察树脂显色后若全部为白色则表示反应完全。反应完成后用DMF/异丙醇 /DMF依次清洗树脂,清洗完后将树脂抽干。脱除Fmoc操作同(3)。
(9)裂解:配制裂解液(TFA:TIS:H2O=15:0.9:0.9)10mL,取5mL裂解液加入树脂中,摇床振摇(34℃,240r/min)2h后,将反应液滤至冷却的乙醚中重结晶,然后将剩余的5mL裂解液再次加入树脂中反应2h,合并滤液于冷却的乙醚中,并将其于-20℃中静置2h。最后通过离心将乙醚中析出的白色固体收集到离心管中,并用氩气吹干得到糖肽化合物8(15mg, 10.6μmol,31%)。
三、氟代TF-MUC1糖肽缀合物的合成
取糖肽化合物8(15mg,10.6μmol)于10mL小烧瓶中,向其中加入2mL水合肼,室温条件下搅拌3h,反应完成后旋蒸浓缩,通过MALDI-TOF MS确定其分子量。C18反相半制备液相柱纯化得到脱乙酰化产物9(10mg,8.7μmol,82%)。
将化合物9(5mg,4.3μmol)溶于EtOH/H2O(2mL,1:1)中,随后缓慢加入方酸二乙酯(3.84μL,26.1μmol),滴加饱和Na2CO3溶液至反应液pH为8.0。室温搅拌3h后,滴加冰醋酸猝灭反应。将反应液旋蒸浓缩,通过MALDI-TOF MS以DHB为基质确定其分子量。用C18反相半制备液相柱纯化,冻干得到产物10(4.9mg,3.8μmol,88%)。化合物10的分子量和纯度表征:MALDI-TOF MS:m/z for C47H79FN10O22[M+H]+calcd:1155.543,found: 1155.543,如图2所示。C18分析HPLC:流动相A:乙腈(含0.1%TFA);流动相B:水;保留时间Rt=10.5min(梯度洗脱30min,5-30%的流动相A,C-18column,λ=220nm),如图3所示。
取蛋白BSA(3.2mg,0.048μmol)溶于0.5mL缓冲液(Na2B4O7 0.07 mol/L,KHCO30.035 mol/L,pH9.0)中,加入化合物10(3mg,2.3μmol),将混合液置于摇床上室温缓慢振摇2 d。反应结束后超滤,冻干,得到白色固体,即为氟代TF-MUC1糖肽缀合物V1(氟代 TF-MUC1-BSA,2.9mg)。通过MALDI-TOF MS确定糖肽与蛋白结合量,如图4所示。
四、氟代TF-MUC1糖肽缀合物的免疫原性测定
取6-8周Balb/c小鼠,每组四只,实验组小鼠分别用步骤三中制备的代TF-MUC1糖肽缀合物V1和同样方法制备的对照品V2(TF-MUC1-BSA)的溶液进行颈部皮下注射,每只小鼠每次免疫注射1μg糖肽(50μLPBS+50μL弗氏佐剂的乳化液),免疫三次,每次免疫间隔两周,第一次免疫用完全弗氏佐剂,后两次免疫用不完全弗氏佐剂。第三次免疫后两周(第 42天),分别对实验组和空白组小鼠进行眼球取血,随即将血液2500rpm/min离心两次,每次10分钟,收集上层血清于EP管中,-20℃保存。
制备抗血清研究其免疫原性,用对照品糖肽的OVA缀合物作为固定抗原,以酶联免疫法 (ELISA)检测糖肽特异性抗体的滴度,免疫滴度的结果如图5所示。经过免疫后,小鼠血清中IgG抗体滴度水平显著增高,免疫应答强烈,而且显示出剂量依赖性,说明缀合物诱导产生的免疫响应主要是IgG型,属于T细胞参与的免疫应答,此应答能够使宿主细胞产生免疫记忆,促进抗体成熟。动物免疫实验结果表明氟代TF-MUC1糖肽缀合物是一种非常有潜力的肿瘤疫苗。
尽管为说明目的公开了本发明的实施例,但是本领域的技术人员可以理解:在不脱离本发明及所附权利要求的精神和范围内,各种替换、变化和修改都是可能的,因此,本发明的范围不局限于实施例所公开的内容。
Claims (9)
1.一种氟代TF-MUC1糖肽缀合物,其特征在于:所述糖肽缀合物的结构通式如下:
其中,糖肽是如下通式(I)中的任一糖肽:
式(Ⅰ)和式(Ⅱ)中:
m是0到30中的任意一个整数;
R=GalNAcα,GalNAcβ,GlcNAcα,GlcNAcβ,Galβ1-3GalNAcα,Galβ1-3GalNAcβ或上述糖基的氟代衍生物;
连接体是糖肽与载体蛋白直接或间接连接后得到的结构部分;
n是载体蛋白连接的寡糖的数量,n是0到30中的任意一个整数;
载体蛋白选自:牛血清白蛋白、人血清白蛋白、血蓝蛋白、破伤风毒素、白喉毒素或白喉毒素无毒突变体。
8.如权利要求1至6任一项所述的氟代TF-MUC1糖肽缀合物在制备疫苗方面中的应用。
9.根据权利要求8所述的应用,其特征在于:所述疫苗为肿瘤疫苗。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010118019.1A CN111423514A (zh) | 2020-02-26 | 2020-02-26 | 一种氟代tf-muc1糖肽缀合物及其制备方法和应用 |
US17/007,805 US20210260204A1 (en) | 2020-02-26 | 2020-08-31 | Fluoro-tf-muc1 glycopeptide conjugate, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010118019.1A CN111423514A (zh) | 2020-02-26 | 2020-02-26 | 一种氟代tf-muc1糖肽缀合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111423514A true CN111423514A (zh) | 2020-07-17 |
Family
ID=71547199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010118019.1A Withdrawn CN111423514A (zh) | 2020-02-26 | 2020-02-26 | 一种氟代tf-muc1糖肽缀合物及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20210260204A1 (zh) |
CN (1) | CN111423514A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306586A (zh) * | 2022-01-04 | 2022-04-12 | 天津科技大学 | 基于tf抗原和壳寡糖内源性佐剂的肿瘤疫苗、方法和应用 |
-
2020
- 2020-02-26 CN CN202010118019.1A patent/CN111423514A/zh not_active Withdrawn
- 2020-08-31 US US17/007,805 patent/US20210260204A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
AN XIAO等: "Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.", 《ORG. BIOMOL. CHEM.》 * |
DONELLA M. BECKWITH等: "Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design", 《SEMINARS IN IMMUNOLOGY》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306586A (zh) * | 2022-01-04 | 2022-04-12 | 天津科技大学 | 基于tf抗原和壳寡糖内源性佐剂的肿瘤疫苗、方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US20210260204A1 (en) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Danishefsky et al. | From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate‐based anticancer vaccines | |
Grigalevicius et al. | Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines | |
Kuduk et al. | Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: The preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer | |
Wang et al. | Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study | |
JP5484668B2 (ja) | モノクローナル抗体mbr1によって同定される乳ガン関連抗原の合成及びこれらの使用 | |
RU2141527C1 (ru) | Синтетический пептид, синтетический липопептид, иммуногенный конъюгат (варианты), способ получения олигомера, защищенный твердым монометиловым эфиром полиэтиленгликоля полисахарид | |
US6645935B2 (en) | Synthesis of glycoconjugates of the lewis Y epitope and uses thereof | |
US20070134259A1 (en) | Methods and compositions for pharmacologially controlled targeted immunotherapy | |
US20040102607A1 (en) | Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof | |
Xiao et al. | Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines | |
CN103108654A (zh) | 多价糖肽构建体及其用途 | |
WO2006017180A2 (en) | Glycopeptide dimers and uses thereof | |
Zheng et al. | Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen | |
WO1996040198A1 (en) | Synthesis of asparagine-linked glycopeptides on a polymeric solid support | |
Wu et al. | Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen–Friedenreich conjugate | |
JP2006514981A (ja) | Gp120特異抗原、その結合体;その調製と使用のための方法 | |
EP1210355B1 (en) | Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof | |
CN111423514A (zh) | 一种氟代tf-muc1糖肽缀合物及其制备方法和应用 | |
CN113995834A (zh) | 一种基于环糊精接枝壳聚糖的疫苗、制备方法及应用 | |
Hevey et al. | Conjugation Strategies Used for the Preparation of Carbohydrate‐Conjugate Vaccines | |
WO2011153815A1 (zh) | 唾液酸(α-(2→6))-D-吡喃糖衍生物及其合成方法和应用 | |
Fujita et al. | Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates | |
US20080213297A1 (en) | Method of producing conjugate vaccines | |
WO2002032963A1 (en) | Immunoadjuvant systems | |
Fiore et al. | Chemical synthesis of carbohydrate-based vaccines against cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200717 |